Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
96 studies found for:    Medivation
Show Display Options
RSS Create an RSS feed from your search for:
Medivation
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: Placebo;   Drug: Paclitaxel
2 Not yet recruiting A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
Condition: Ovarian Cancer
Interventions: Drug: Talazoparib;   Drug: Temozolomide
3 Recruiting A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
Conditions: Prostate Carcinoma Metastatic to the Bone;   Castration Resistant Prostate Cancer
Intervention: Drug: Enzalutamide
4 Recruiting Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Conditions: Hormone Sensitive Prostate Cancer;   Prostate Cancer;   Cancer of the Prostate
Interventions: Drug: Enzalutamide;   Drug: Placebo;   Drug: Leuprolide
5 Recruiting Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Conditions: Nonmetastatic Castration-Resistant Prostate Cancer;   Prostate Cancer;   Cancer of the Prostate
Interventions: Drug: Enzalutamide;   Drug: Placebo
6 Active, not recruiting Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: MDV3100
7 Recruiting A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Conditions: Breast Neoplasms;   BRCA 1 Gene Mutation;   BRCA 2 Gene Mutation
Interventions: Drug: talazoparib;   Drug: Physician's-Choice
8 Not yet recruiting Open-Label Extension and Safety Study of Talazoparib
Condition: Cancer
Intervention: Drug: Talazoparib
9 Approved for marketing A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Condition: Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: abiraterone acetate;   Drug: prednisone
10 Active, not recruiting Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: exemestane;   Drug: Placebo (for enzalutamide)
11 Active, not recruiting Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Condition: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Intervention: Drug: Enzalutamide
12 Active, not recruiting
Has Results
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: Bicalutamide
13 Active, not recruiting Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Condition: Breast Cancer
Interventions: Drug: enzalutamide;   Drug: anastrozole;   Drug: exemestane;   Drug: fulvestrant
14 Active, not recruiting Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Conditions: Advanced or Recurrent Solid Tumors;   Breast Neoplasms;   Ovarian Cancer, Epithelial;   Ewing Sarcoma;   Small Cell Lung Carcinoma;   Prostate Cancer;   Pancreas Cancer
Intervention: Drug: Talazoparib
15 Completed A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Dimebon;   Drug: Placebo
16 Active, not recruiting A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
Conditions: Prostate Cancer;   Hormone Refractory Prostate Cancer
Intervention: Drug: MDV3100
17 Withdrawn Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Conditions: Lymphoma, Large B-Cell, Diffuse;   Primary Mediastinal Large B-cell Lymphoma;   Transformed Indolent Lymphoma
Intervention: Biological: MDV9300
18 Active, not recruiting Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
Condition: Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: Abiraterone;   Drug: Placebo for Enzalutamide;   Drug: Prednisone
19 Active, not recruiting A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
Conditions: Breast Neoplasms;   BRCA 1 Gene Mutation;   BRCA 2 Gene Mutation
Intervention: Drug: talazoparib
20 Completed Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
Condition: Human Volunteers
Intervention: Drug: BMN 673

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.